Ligand Pharmaceuticals Incorporated (LGND) Q2 2019 Earnings Results

Ligand Pharmaceuticals Misses on EPS, Stock Down 11.38%

Ligand Pharmaceuticals reported lower-than-expected earnings per share, which contributed to a significant drop in stock price. The lack of revenue data and guidance left investors uncertain about the company's future performance. The 11.38% decline in stock price reflects market disappointment and concerns over ongoing challenges.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.68	N/A	-13.53%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed concerns about the current market conditions impacting performance. They remain committed to their long-term goals.

Management acknowledged the challenges faced in the quarter.

They emphasized a focus on long-term strategies despite short-term hurdles.

Ligand Pharmaceuticals Misses on EPS, Stock Down 11.38%

Key numbers

Management commentary

Ligand Pharmaceuticals Incorporated

More earnings this week

Ligand Pharmaceuticals Misses on EPS, Stock Down 11.38%

Key numbers

Management commentary